Hair Transplant for Lichen Planopilaris: What to Assess Before Considering Surgery

What Is Lichen Planopilaris?

Lichen planopilaris is a primary lymphocytic scarring alopecia. Classic LPP commonly produces irregular single or multifocal patches, often involving the vertex or other scalp areas, which is different from frontal fibrosing alopecia (FFA), a condition within the LPP spectrum that instead follows a characteristic frontotemporal hairline band with frequent eyebrow involvement.

LPP may also affect the skin, mouth, nails or body hair as part of the broader lichen planus spectrum. A consultation should ask about these findings, since they can support diagnosis and influence a patient's wider dermatology care.

Why Does LPP Cause Permanent Scarring Hair Loss?

The immune process in LPP targets the hair follicle directly. Once a follicle is destroyed and replaced by fibrous tissue, natural regrowth is usually not expected. The goal of medical treatment is to reduce inflammation, slow progression and relieve symptoms, not to regrow follicles that scarring has already replaced.

Can a Hair Transplant Help LPP?

A transplant may improve the appearance of carefully selected patients with inactive, end-stage LPP, but it does not cure the inflammatory disease or restore follicles already destroyed by scarring. Graft survival can be lower or less predictable than in non-scarring alopecia, which is why candidacy requires specialist assessment rather than a standard consultation checklist.

Inactive disease is not the same as cured disease. LPP may become inactive, but the hair loss from scarring is usually permanent, and the disease itself can be unpredictable. A quiet period lowers concern; it does not eliminate future reactivation risk.

Why Active LPP Is Not Suitable for Routine Surgery

Surgery is generally deferred when LPP is active or progressing. New hair loss, perifollicular redness, perifollicular scale or hyperkeratosis, and symptoms such as itch, burning or tenderness all require dermatology assessment and disease management before cosmetic restoration is considered. The target tissue in LPP may have reduced vascularity, altered thickness or poor pliability, and operating into an actively inflamed area risks poor graft uptake and can complicate the clinical picture.

How Doctors Diagnose and Monitor LPP

Clinical Examination

The dermatologist assesses the scalp pattern, follicular openings, scar texture, symptoms and progression. LPP may show smooth or shiny hairless patches, irregular loss of follicular openings and perifollicular inflammation at the active edge. The clinician also inspects the mouth, nails, skin and body hair for associated lichen-planus findings. A history of itch, burning, pain, tenderness or scalp sensitivity is relevant, though symptoms are not present in every patient.

Trichoscopy

Trichoscopy is a magnified examination of the scalp and hair. Characteristic LPP findings can include absent follicular openings, white dots, tubular perifollicular scale and perifollicular erythema. It serves two roles before transplantation: supporting diagnosis and helping identify the best biopsy site when one is needed, and documenting whether signs of activity are persisting or changing over time. A trichoscopy photograph is not a self-diagnosis; perifollicular redness can be subtle, and scarred areas may show few inflammatory signs even though the underlying diagnosis remains important.

Biopsy

A scalp biopsy may be required when the pattern is atypical or when LPP must be distinguished from discoid lupus erythematosus, central centrifugal cicatricial alopecia, folliculitis decalvans, alopecia areata or another condition. Trichoscopy can help select the biopsy site, and histopathology documents fibrosis and the inflammatory process. Biopsy is not automatically required for every patient; your dermatologist may recommend one when the diagnosis or activity is uncertain.

How Long Should LPP Be Inactive Before Transplantation?

Published recommendations and clinical practices vary, and a patient should not decide that LPP is inactive based only on the absence of symptoms. A careful assessment may include no new or enlarging alopecic patches; no visible progression on serial standardized photographs; no new symptoms such as itch, burning, pain or tenderness attributable to LPP; no convincing perifollicular erythema or scale at the active margin; no worsening hyperkeratosis or follicular casts on trichoscopy; stable examination findings over time; a reviewed treatment history and medication plan; an adequate, healthy donor area; and no competing active scarring alopecia. A pull test may be part of a clinician's overall assessment, but unpublished thresholds from any single clinic page should not be treated as universal guidelines.

Published case reports describe waiting at least one year without disease activity, while other sources discuss a remission period of 12 to 24 months, and one clinical page recommends ideally two years. A 2026 systematic review found that published inactive periods ranged from zero months to more than three years across the studies it reviewed, which is a major reason we don't present a simple "safe after one year" or "safe after two years" promise. Many specialists use a prolonged period of stability, often at least 12 to 24 months and sometimes longer, but the final decision depends on disease history, examination, trichoscopy, photographs, biopsy when needed, treatment status and donor-recipient suitability, not a calendar date alone.

Who May Be a Candidate?

A potential candidate may have a confirmed or well-supported LPP diagnosis; inactive disease with no convincing progression during the observation period; no current inflammatory symptoms that raise concern; no active perifollicular erythema, scale or hyperkeratosis requiring treatment; a dermatologist-directed plan for monitoring and treatment; sufficient healthy donor hair; recipient tissue with enough pliability and vascularity to support grafts; a localized or realistically treatable area; realistic expectations about density and possible graft loss; and willingness to return for long-term follow-up.

A patient may be unsuitable or not ready if LPP is active, rapidly progressing or diagnostically uncertain; the disease has recently required escalation of treatment; symptoms are recurring or uncontrolled; the donor area is scarred, inflamed or diffusely miniaturized; the recipient scar is severely atrophic, hypertrophic or poorly vascularized; the patient wants a dense, low hairline or complete coverage the donor supply cannot support; the patient refuses dermatology follow-up or prescribed treatment; the patient expects a standard androgenetic-alopecia-like permanent result; or an alternative diagnosis such as discoid lupus or folliculitis decalvans has not been excluded.

Donor-Area and Recipient-Scar Assessment

Donor Area

The donor area must be examined rather than assumed to be permanent. Classic LPP can involve multiple scalp sites, and scarring or miniaturization in the occipital or parietal region may reduce available grafts. The surgeon should assess density, hair calibre, miniaturization, follicular-unit quality, scalp laxity and possible future loss. In a published 2016 case report, a patient with extensive scarring across multiple scalp regions required unaffected scalp and beard follicles for additional grafts; that is a selected case and not a reason to promise body-hair transplantation to every patient.

Recipient Tissue

Scarred recipient tissue can have reduced and uneven perfusion. It may be thin, thick, stiff or irregular. Published reviews of hair transplantation in primary cicatricial alopecias identify unpredictable scar vascularity, unpredictable graft survival, risk of relapse, donor insufficiency and the need for multiple sessions as key challenges. Low-density and staged placement may be discussed when tissue quality is uncertain; the aim is to use donor supply conservatively and observe how grafts behave in the recipient environment, not to maximize graft count in one sitting.

Test Grafts

A test graft is a small procedure that can help assess recipient uptake before larger surgery. One published case used an initial 50-graft test patch and reported approximately 80% growth at 10 months before proceeding to a larger session. That result is clinically interesting but cannot be generalized; a test patch does not guarantee that other scarred areas will behave the same way, and it cannot rule out later LPP reactivation.

FUE Versus FUT for LPP

FUE removes individual follicular units from the donor area. It may allow dispersed harvesting and can be considered when a linear incision is undesirable or when donor scarring makes strip harvesting unsuitable. It still creates small donor scars, can deplete the donor area and does not eliminate recipient-disease risk.

FUT removes a strip of donor scalp and leaves a linear scar. It may provide an efficient harvest in some patients, but it requires suitable scalp laxity and donor tissue, and existing donor scarring or diffuse disease may make it inappropriate.

For LPP, neither FUE nor FUT removes the inflammatory risk. Technique choice depends on diagnosis, disease stability, donor health, scar pattern, recipient tissue, graft requirements and long-term planning, not on which method is marketed as superior.

Medical Treatment Before and After Surgery

Active or progressive LPP requires dermatologist-directed management. Treatments used in practice include topical or intralesional corticosteroids, hydroxychloroquine, tetracyclines, systemic immunomodulators and other options selected according to the patient. This page does not prescribe a medication, dose or taper schedule; treatment depends on pregnancy potential, comorbidities, laboratory and eye monitoring, age, concurrent conditions, disease severity and the dermatologist's judgment.

A surgical consultation should ask what treatment the patient has used, when the last flare or treatment escalation occurred, whether treatment has been stopped, continued or changed, whether the disease is quiet because of treatment or because it has remained inactive without treatment, what monitoring will continue after surgery, and what symptoms or trichoscopic changes should trigger reassessment. Some clinicians continue or restart medical treatment after transplantation; that decision is individualized by the treating dermatologist, not a universal Kibo prescription.

Results, Graft Survival and Realistic Expectations

A 2026 systematic review of hair transplantation in LPP and FFA included 13 studies involving 113 patients, all classified as level 4 evidence (case reports or case series). Across studies with six to 12 month follow-up, 92 of 94 patients were reported to have favorable hair growth, with survival values ranging from 80% to 100% in most of those reports. Short follow-up can overstate durability, and in longer follow-up, outcomes were more variable: the review's dataset included a classic LPP case with an initially excellent result at 15 months but no regrowth at four years after active treatment was stopped, alongside a long-term FUE study reporting approximately 78.62% survival at 12 months and 79.96% at 24 months. Other case series reported favorable short-term growth but poor results at three to four years. These differences may reflect disease phenotype, activity, treatment, scar vascularity, technique, measurement method and publication bias; a favorable case report shows that success can occur, it does not predict an individual patient's result.

A separate 2025 five-patient case series required confirmed LPP using trichoscopy and histopathology, with no active disease at qualification, and reported no adverse events and rising patient satisfaction at one year, though some patients had second procedures. That study is useful because it describes a strict diagnostic and surgical pathway, but it is not a controlled trial and it used an individualized protocol that included platelet-rich plasma (PRP) and light therapy; we do not attribute its reported outcome to PRP or any single adjunct, since the evidence for that specific claim is not established.

A 2016 case report described a patient with inactive, end-stage LPP who had been off medication for two years without new patches or progression. A 50-graft test patch showed approximately 80% growth at 10 months, after which additional scalp and beard grafts were placed; at 10 months after the larger procedure, about 80% of grafts were reported to have survived. This case demonstrates the potential value of disease stability, test grafting, vascularity assessment and conservative donor planning; it describes one patient with limited follow-up and cannot establish a general success rate.

Reactivation and Postoperative LPP

A published report described patients evaluated for poor growth after hair transplantation, where dermatoscopy and biopsy confirmed LPP, including perifollicular erythema and scale. The possibility was discussed that surgical trauma could contribute through a Koebner phenomenon, an immune response to follicular material released during surgery or to a postsurgical inflammatory environment. This does not prove that transplantation caused every case; patients may have had undiagnosed scarring alopecia before surgery. The practical message is that surgeons should maintain suspicion, examine graft-loss patients with trichoscopy and use biopsy when needed.

LPP may be recognized or develop after transplantation in susceptible patients, and surgical trauma may be relevant. This is one reason preoperative diagnosis, activity assessment and long-term surveillance are essential, not optional add-ons.

Early shedding or temporary changes after surgery should not be confused with disease relapse. A clinician should distinguish routine postoperative changes from new inflammatory activity; redness, scale, pain, expanding loss, shiny scar formation or worsening symptoms require assessment rather than reassurance through generic aftercare content. Follow-up should assess donor healing and visible scarring, recipient inflammation and wound healing, graft growth over time, new native hair loss, symptoms such as itch, burning or pain, trichoscopic changes, patient satisfaction and realistic density, and whether further surgery is appropriate. Long-term photographs should use comparable lighting, camera angle, hair length and parting; before-and-after images without follow-up duration are not sufficient evidence of durable success.

Alternatives When Surgery Is Not Suitable

Options include dermatologist-directed treatment and monitoring; wigs and hairpieces; cosmetic camouflage fibres or sprays, with a clear statement that they do not treat LPP; scalp micropigmentation after medical assessment; carefully selected hair-length or parting approaches that do not create traction; eyebrow cosmetics or prosthetic options when eyebrow involvement is present; and psychological support when visible scarring alopecia affects confidence or daily functioning. For active or uncertain LPP, these options may offer coverage without introducing surgical trauma while the disease is still being evaluated.

Cost and Consultation Transparency

A generic per-graft price is not enough for LPP. The final plan may involve a dermatologist review, trichoscopy, biopsy, a test graft, staged procedures, special scar-tissue planning, limited density and long-term follow-up. A responsible consultation document should state the working diagnosis and whether biopsy or additional dermatology review is needed; the evidence supporting inactivity; the length and quality of the stable period; findings from serial photographs and trichoscopy; donor-area health and future donor reserve; recipient-scar quality and realistic density; whether a test graft or staged procedure is advised; the technique and why it was chosen; expected outcomes and the possibility of poor or declining graft survival; medical treatment and monitoring responsibilities; what is included in the quoted cost; and what happens if the disease reactivates or graft growth is poor. We don't publish a routine androgenetic-alopecia cost range as though it applies to LPP.

Bottom Line

A hair transplant for lichen planopilaris can be a reasonable option for carefully selected, inactive, end-stage patients, but it is not routine transplant territory while the disease is active or uncertain. Kibo's approach is diagnosis and activity assessment first, honest discussion of donor supply and scar-tissue quality, and long-term follow-up, backed by our No Ghost Surgery pledge and a 12-month care journey.